Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
- Conditions
- Mycobacterium Avium-intracellulare InfectionHIV Infections
- Registration Number
- NCT00002267
- Lead Sponsor
- Pharmacia
- Brief Summary
The primary objective of this trial is to assess the safety and the relative benefit of rifabutin monotherapy in preventing or delaying the incidence of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200, as compared to placebo, and to assess if survival is prolonged in patients who receive rifabutin prophylaxis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 750
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (43)
Maricopa County Med Ctr
🇺🇸Phoenix, Arizona, United States
East Bay AIDS Ctr
🇺🇸Berkeley, California, United States
Pacific Oaks Med Group
🇺🇸Beverly Hills, California, United States
AIDS Community Research Consortium
🇺🇸Redwood City, California, United States
HIV Research Group
🇺🇸San Diego, California, United States
Dr Larry A Waites
🇺🇸San Francisco, California, United States
Saint Francis Mem Hosp / HIV Care
🇺🇸San Francisco, California, United States
Dr Marcus Conant
🇺🇸San Francisco, California, United States
San Francisco Veterans Administration Med Ctr
🇺🇸San Francisco, California, United States
Dr Marshall Kubota
🇺🇸Santa Rosa, California, United States
Scroll for more (33 remaining)Maricopa County Med Ctr🇺🇸Phoenix, Arizona, United States